Novo Nordisk announced today that Health Canada has approved Ozempic® (semaglutide injection) to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction ...

Canada can build successful diabetes prevention and remission programs across the country by learning from England, a Quebec-based team of clinician-scientists and other experts suggested. England’s ...

Canada can learn from England’s successful diabetes prevention program to build its own programs to tackle diabetes prevention across the country, argue authors in ...

Health Canada on Tuesday approved Novo Nordisk's (NYSE:NVO) Ozempic (semaglutide) to reduce the risk of kidney disease and cardiovascular deaths in adults with type 2 diabetes. The approval makes ...

Aspen Pharmacare, a South African drugmaker, plans to enter the Canadian market with a generic version of Novo Nordisk’s blockbuster diabetes and weight-loss drug Ozempic by the third quarter of 2026.

Type 2 diabetes, linked to insulin resistance, affects a significant portion of the American population, many undiagnosed. Pre-diabetes, also caused by insulin resistance, often progresses to Type 2 ...

Ozempic (R) was approved by Health Canada in 2018. Ozempic (R) is indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control.